Nephros Inc.

3960 Broadway
New York
New York
10032
United States

Tel: 212-781-5113
Fax: 212-781-5166

Email: info@nephros.com

Show jobs for this employer

173 articles with Nephros Inc.

  • Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will file its second quarter 2020 financial results on Wednesday, August 5, 2020 and will host a conference call that same day at 4:30 PM ET, during which management will discuss the company's financial results and provide

  • Nephros SequaPath™, a new microbial screening system, used to evaluate 88 building water samples across four US geographic regions

  • Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will be presenting virtually at the upcoming Zooming with LD event on Thursday, July 23rd at 11:00 AM ET.

  • Nephros , Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced preliminary financial results for the quarter ended June 30, 2020. Net revenues for the quarter are expected to be $1.6 million, a decrease of approximately 33% compared

  • Nephros, Inc.(Nasdaq:NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2020 Russell indexes annual reconstitution,

  • Nephros, Inc. (Nasdaq: NEPH ), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will be presenting at the upcoming Virtual Summer Summit on Tuesday, June 9 th at 10:55 AM ET. Andy Astor, COO & CFO of Nephros, will be giving the presentation and answering questions from i

  • Nephros, Inc. announced that, due to the public health concerns associated with the ongoing coronavirus outbreak and to support the health and well-being of its stockholders, employees, and other partners, the location of the 2020 Annual Meeting of Stockholders of Nephros, Inc. has been changed.

  • Nephros, Inc., a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, announced financial results for the three months ended March 31, 2020.

  • Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will file its first quarter 2020 financial results on Wednesday, May 6, 2020 and will host a conference call that same day at 4:30 PM ET, during which management will discuss the company's financial result

  • Anticipates $2.6 Million Net Revenues, Approximately 45% Growth Over 2019

  • Specialty Renal Products, Inc., a subsidiary of Nephros, Inc., a medical device company that develops and sells a hemodiafiltration system for the treatment of patients with end stage renal disease, announced that it has hired Tony Robinson as Vice President of Operations.

  • Nephros, Inc.(Nasdaq: NEPH), a commercial stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will be presenting at the Sidoti Spring 2020 Investor Conference on Thursday, March 26that 9:10 am EDT. Andy Astor, COO & CFO of Nephros, 

  • Nephros, Inc. (Nasdaq:NEPH), a commercial stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced financial results for the fourth quarter and full year ended December 31, 2019.

  • Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will file its fourth quarter and full year 2019 financial results on Thursday, February 27, 2020 and will host a conference call that same day at 4:30 PM ET,

  • Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a  commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced the pricing of a firm commitment underwritten offering of 937,500 shares of common stock at a price to the public of $8.00 per share for aggregate gross proceeds of approximately $7,500,000,

  • Nephros, Inc. announced that it has formally launched PluraPathTM, the only commercially available portable water pathogen detection system designed to provide actionable data for infection control teams on up to 15 different pathogens from a single water sample, in approximately one hour.

  • Nephros, Inc. announced preliminary financial results for the fiscal year ended December 31, 2019.

  • Nephros, Inc. announced financial results for the three months ended September 30, 2019.

  • Nephros, Inc. (Nasdaq: NEPH), a commercial stage company that develops and sells high performance water purification products to the medical device and commercial markets, today announced that it will file its third quarter 2019 financial results on Wednesday, November 6, 2019

  • Nephros, Inc. (Nasdaq: NEPH), a commercial stage company that develops and sells high performance water purification products to the medical device and commercial markets, will visit the Nasdaq MarketSite in Times Square